Log in
NYSE:JNJ

Johnson & Johnson Stock Forecast, Price & News

$144.00
+0.32 (+0.22 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$143.22
Now: $144.00
$144.66
50-Day Range
$137.11
MA: $145.23
$151.84
52-Week Range
$109.16
Now: $144.00
$157.00
Volume3.06 million shs
Average Volume8.09 million shs
Market Capitalization$379.09 billion
P/E Ratio22.64
Dividend Yield2.81%
Beta0.69
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular diseases; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Read More
Johnson & Johnson logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.5Dividend Strength: 4.2Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.52 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP47816010
Phone732-524-0400
Employees132,200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$82.06 billion
Cash Flow$11.90 per share
Book Value$24.49 per share

Profitability

Net Income$15.12 billion

Miscellaneous

Outstanding Shares2,632,543,000
Market Cap$379.09 billion
Next Earnings Date1/27/2021 (Estimated)
OptionableOptionable
$144.00
+0.32 (+0.22 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive JNJ News and Ratings via Email

Sign-up to receive the latest news and ratings for JNJ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Johnson & Johnson (NYSE:JNJ) Frequently Asked Questions

How has Johnson & Johnson's stock been impacted by COVID-19?

Johnson & Johnson's stock was trading at $131.80 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, JNJ shares have increased by 9.3% and is now trading at $144.00.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Johnson & Johnson?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Johnson & Johnson
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Johnson & Johnson?

Wall Street analysts have given Johnson & Johnson a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Johnson & Johnson wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Johnson & Johnson's next earnings date?

Johnson & Johnson is scheduled to release its next quarterly earnings announcement on Wednesday, January 27th 2021.
View our earnings forecast for Johnson & Johnson
.

How were Johnson & Johnson's earnings last quarter?

Johnson & Johnson (NYSE:JNJ) released its earnings results on Sunday, October, 18th. The company reported $2.20 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.98 by $0.22. The business earned $21.08 billion during the quarter, compared to analyst estimates of $20.15 billion. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The business's revenue for the quarter was up 1.7% on a year-over-year basis. During the same quarter last year, the firm earned $2.12 earnings per share.
View Johnson & Johnson's earnings history
.

How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?

Johnson & Johnson declared a quarterly dividend on Thursday, October 22nd. Investors of record on Tuesday, November 24th will be paid a dividend of $1.01 per share on Tuesday, December 8th. This represents a $4.04 annualized dividend and a dividend yield of 2.81%. The ex-dividend date of this dividend is Monday, November 23rd.
View Johnson & Johnson's dividend history
.

How will Johnson & Johnson's stock buyback program work?

Johnson & Johnson declared that its board has authorized a stock repurchase program on Monday, December 17th 2018, which allows the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase up to 1.5% of its stock through open market purchases. Stock buyback programs are often a sign that the company's leadership believes its stock is undervalued.

What guidance has Johnson & Johnson issued on next quarter's earnings?

Johnson & Johnson updated its FY20 earnings guidance on Tuesday, October, 13th. The company provided EPS guidance of $7.95-8.05 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.89. The company issued revenue guidance of 0.0-1.0% to ~$82.0-82.8, compared to the consensus revenue estimate of $80.66 billion.

What price target have analysts set for JNJ?

13 brokerages have issued twelve-month price targets for Johnson & Johnson's stock. Their forecasts range from $155.00 to $182.00. On average, they anticipate Johnson & Johnson's stock price to reach $166.08 in the next twelve months. This suggests a possible upside of 15.3% from the stock's current price.
View analysts' price targets for Johnson & Johnson
.

Are investors shorting Johnson & Johnson?

Johnson & Johnson saw a increase in short interest in October. As of October 30th, there was short interest totaling 12,770,000 shares, an increase of 13.9% from the October 15th total of 11,210,000 shares. Based on an average daily volume of 6,420,000 shares, the short-interest ratio is presently 2.0 days. Approximately 0.5% of the shares of the stock are sold short.
View Johnson & Johnson's Short Interest
.

Who are some of Johnson & Johnson's key competitors?

What other stocks do shareholders of Johnson & Johnson own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Johnson & Johnson investors own include AT&T (T), Pfizer (PFE), Verizon Communications (VZ), The Walt Disney (DIS), NVIDIA (NVDA), Intel (INTC), JPMorgan Chase & Co. (JPM), Cisco Systems (CSCO), The Procter & Gamble (PG) and AbbVie (ABBV).

Who are Johnson & Johnson's key executives?

Johnson & Johnson's management team includes the following people:
  • Mr. Alex Gorsky, Chairman & CEO (Age 60, Pay $5.58M)
  • Mr. Joseph J. Wolk CPA, Exec. VP & CFO (Age 53, Pay $2.01M)
  • Dr. Paulus A. Stoffels, Chief Scientific Officer (Age 58, Pay $3.68M)
  • Mr. Joaquin Duato, Vice Chairman of Exec. Committee (Age 57, Pay $3.35M)
  • Ms. Jennifer L. Taubert, Exec. VP & Worldwide Chairman of Pharmaceuticals (Age 56, Pay $2.04M)
  • Mr. Robert J. Decker Jr., Controller & Chief Accounting Officer (Age 48)
  • Mr. James Swanson, Exec. VP & Global CIO
  • Mr. Christopher DelOrefice, VP of Investor Relations
  • Mr. Michael H. Ullmann, Exec. VP & Gen. Counsel (Age 61)
  • Ms. Ashley Watson, Chief Compliance Officer (Age 51)

What is Johnson & Johnson's stock symbol?

Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."

Who are Johnson & Johnson's major shareholders?

Johnson & Johnson's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.36%), State Street Corp (5.69%), Massachusetts Financial Services Co. MA (1.12%), Morgan Stanley (0.85%), Charles Schwab Investment Management Inc. (0.59%) and Nuveen Asset Management LLC (0.54%). Company insiders that own Johnson & Johnson stock include Ashley Mcevoy, Charles Prince, Hubert Joly, Kathryn E Wengel, Marillyn A Hewson, Michael E Sneed, Peter Fasolo, Ronald A Kapusta and William D Perez.
View institutional ownership trends for Johnson & Johnson
.

Which institutional investors are selling Johnson & Johnson stock?

JNJ stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, CIBC Private Wealth Group LLC, Nuveen Asset Management LLC, Charles Schwab Investment Management Inc., UBS Asset Management Americas Inc., State of Tennessee Treasury Department, The Manufacturers Life Insurance Company, and Hexavest Inc.. Company insiders that have sold Johnson & Johnson company stock in the last year include Ashley Mcevoy, Kathryn E Wengel, and Michael E Sneed.
View insider buying and selling activity for Johnson & Johnson
.

Which institutional investors are buying Johnson & Johnson stock?

JNJ stock was bought by a variety of institutional investors in the last quarter, including Natixis, Voloridge Investment Management LLC, Polar Capital LLP, Boston Partners, Morgan Stanley, California Public Employees Retirement System, Ossiam, and CIBC Private Wealth Group LLC. Company insiders that have bought Johnson & Johnson stock in the last two years include Charles Prince, Hubert Joly, Marillyn A Hewson, and William D Perez.
View insider buying and selling activity for Johnson & Johnson
.

How do I buy shares of Johnson & Johnson?

Shares of JNJ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Johnson & Johnson's stock price today?

One share of JNJ stock can currently be purchased for approximately $144.00.

How big of a company is Johnson & Johnson?

Johnson & Johnson has a market capitalization of $379.09 billion and generates $82.06 billion in revenue each year. The company earns $15.12 billion in net income (profit) each year or $8.68 on an earnings per share basis. Johnson & Johnson employs 132,200 workers across the globe.

What is Johnson & Johnson's official website?

The official website for Johnson & Johnson is www.jnj.com.

How can I contact Johnson & Johnson?

Johnson & Johnson's mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The company can be reached via phone at 732-524-0400.

This page was last updated on 11/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.